What's New in Shock, September 2017?
The Role of Microglia in the Etiology and Evolution of Chronic Traumatic Encephalopathy
Neuroendocrine Derangements in Early Septic Shock : Pharmacotherapy for Relative Adrenal and Vasopressin Insufficiency
Mortality is Greater in Septic Patients With Hyperlactatemia Than With Refractory Hypotension
Comparison of the Performance Between Sepsis-1 and Sepsis-3 in ICUs in China : A Retrospective Multicenter Study
Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock : A Randomized Controlled Pilot Study
Heparin-Binding Protein (HBP) : A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury
Phenotypic Changes and Impaired Function of Peripheral γδ T Cells in Patients With Sepsis
Disseminated Intravascular Coagulation in Emergency Department Patients With Primary Postpartum Hemorrhage
Iloprost, Prostaglandin E1, and Papaverine Relax Human Mesenteric Arteries With Similar Potency
Loss of Syndecan-1 Abrogates the Pulmonary Protective Phenotype Induced by Plasma After Hemorrhagic Shock
Cell-Derived Nanoparticles are Endogenous Modulators of Sepsis With Therapeutic Potential
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis
Hydrogen Gas Protects Against Intestinal Injury in Wild Type But Not NRF2 Knockout Mice With Severe Sepsis by Regulating HO-1 and HMGB1 Release
Effects of Glycyrrhizin on the Differentiation of Myeloid Cells of the Heart and Lungs in Lipopolysaccharide-Induced Septic Mice
Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis